CAJ | 학술논문

目的：探讨索拉非尼治疗晚期肾癌的近期及远期疗效。方法：对2011年8月～2013年8月我院收治的76例晚期肾癌患者的临床资料进行统计分析。结果：观察组患者治疗的总有效率78.95%（30/38）明显比对照组57.89%（22/38）高（P＜0.05），手足皮肤反应、皮疹/溃疡发生率18.42%（7/38）、10.53%（4/38）均明显比对照组(0、0)高（P＜0.05），发热、恶心发生率7.89%（3/38）、2.63%（1/38）均明显比对照组26.32%（10/38）、15.79%（6/38）低（P＜0.05），PF、RF、EF评分均明显比对照组高（P＜0.05），1、3、5年生存率68.4%（26/38）、31.6%（12/38）、21.1%（8/38）均明显比对照组52.6%（20/38）、15.8%（6/38）、5.3%（2/38）高（P＜0.05）。结论：索拉非尼治疗晚期肾癌的近期及远期疗效均较显著。
목적：탐토색랍비니치료만기신암적근기급원기료효。방법：대2011년8월～2013년8월아원수치적76례만기신암환자적림상자료진행통계분석。결과：관찰조환자치료적총유효솔78.95%（30/38）명현비대조조57.89%（22/38）고（P＜0.05），수족피부반응、피진/궤양발생솔18.42%（7/38）、10.53%（4/38）균명현비대조조(0、0)고（P＜0.05），발열、악심발생솔7.89%（3/38）、2.63%（1/38）균명현비대조조26.32%（10/38）、15.79%（6/38）저（P＜0.05），PF、RF、EF평분균명현비대조조고（P＜0.05），1、3、5년생존솔68.4%（26/38）、31.6%（12/38）、21.1%（8/38）균명현비대조조52.6%（20/38）、15.8%（6/38）、5.3%（2/38）고（P＜0.05）。결론：색랍비니치료만기신암적근기급원기료효균교현저。
Objective: To investigate the recent and long-term efficacy of sorafenib in the treatment of advanced renal cell carcinoma.Methods:The clinical data of 76 cases of patients with advanced kidney cancer in our hospital from August 2011 to August 2013 were statistically analyzed.Results:The total effective treatment of patients in the observation group 78.95% (30/38) was signiifcantly higher than the control group 57.89% (22/38) (P<0.05), the hand-foot skin reaction, rash / ulcer incidence 18.42% (7/38), 10.53% (4/38) were significantly higher than the control group(0,0) (P<0.05), the fever, nausea incidence 7.89% (3/38), 2.63% (1/38) were significantly lower than the control group 26.32% (10/38),15.79% (6/38) (P<0.05),the PF,RF,EF scores were significantly higher than the control group (P<0.05),the 1,3,5-year survival rate were 68.4% (26/38),31.6% (12/38),21.1% (8/38) were significantly higher than the control group 52.6% (20/38),15.8% (6/38),5.3% (2/38) (P<0.05).Conclusion:The recent and long-term efficacy of sorafenib is significant in the treatment of advanced renal cell carcinoma,so it is worthy of promoting.